Online citations, reference lists, and bibliographies.

Attribution Of Deaths Following Cancer Treatment.

Colin B. Begg, Deborah Schrag
Published 2002 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Government agencies provide regular reports on progress in the fight against cancer, and these reports are viewed with great interest by researchers and by the media (1). The primary measures of the cancer burden are cancer incidence rates and cancer mortality rates. The latter are derived from state death certificates, which are completed by physicians, medical examiners, coroners, and funeral directors, and collated by the National Center for Health Statistics (NCHS) (2). The data from death certificates are compiled using the World Health Organization schema to determine the underlying cause of death. The classification rules are changed periodically; most recently in 1999 with the adoption of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD) (3). This general approach leads to the designation of a unitary “underlying” cause for each death. In practice, a death may be precipitated by multiple causes. Recently, the NCHS has developed a system for processing multiple classifications, including the use of relevant free text from the death certificate (2). However, the National Cancer Institute continues to report death rates using deaths for which cancer is designated as the sole underlying cause. In this issue of the Journal, Welch and Black (4) raise the concern that cancer death rates are systematically underestimated, in that many patients who die as a result of cancer treatment do not have cancer recorded as the underlying cause of death. The authors assembled data on the reported cause of death for all patients in the Surveillance, Epidemiology, and End Results (SEER) program from 1994 through 1998 who died within 1 month of cancer-directed surgery for one of 19 common solid tumors. They found that for 41% of these deaths, the cause was not attributed to cancer. The authors speculate that cancer treatment is the probable underlying cause for essentially all of these deaths and, as a result, the cancer mortality rate is underestimated by 0.9%. Welch and Black (4) also suggest that many deaths subsequent to 1 month after cancer-directed surgery may be similarly miscoded, leading to further underestimation. We note that the terminology related to death rates can be confusing. The term “cancer mortality rate” is used conventionally to represent a cancer death rate in the total population— where the denominator includes all people in the population with or without the cancer of interest. Thus, the metric is comparable to the “cancer incidence rate” in the population. By contrast, the term “cancer survival” usually refers to the mortality experience (survival rather than death) among patients with a cancer diagnosis. However, in studies of postoperative outcomes, the terms “operative mortality” or “surgical mortality” are often used, although the denominator includes only cancer surgery recipients. To calibrate their calculations throughout their article, Welch and Black (4) used population-based rates. The misattribution of cancer deaths is a long-studied issue (5–8). Welch and Black (4) appear to be especially concerned about systematic underestimation in the context of greater use of cancer screening tests. Greater use of cancer-directed surgery in patients with small, early-stage lesions leading to, presumably, more deaths following a cancer diagnosis that are not attributed to cancer could exaggerate the benefits of screening. Welch and Black (4) propose that for all deaths following cancer treatment—including radiotherapy, chemotherapy, and surgery— cancer should be designated as the underlying cause of death. They propose the development of “simple” though arbitrary rules, such as the designation of any death within 1 month of treatment as a cancer death. Although we agree that continued efforts to refine and improve the classification and reporting of cancer mortality statistics are worthwhile, and indeed are being pursued in the government agencies responsible for reporting vital statistics, the specific ideas proposed by Welch and Black (4) appear to us to be impractical and may themselves introduce inaccuracies. Consider first the proposal to designate all deaths within 1 month of surgery as cancer deaths, and take, as an example, the use of radical prostatectomy for prostate cancer. We know that the 1-month death rate following this procedure in men over 65 years of age is 0.49% (9). Welch and Black (4) would, by their convention, designate all of these deaths as cancer deaths. However, in an elderly population of this nature (i.e., men over age 65 years), the underlying force of mortality is strong. In fact, using death rates for men in the United States from the NCHS (2), adjusted to the age distribution of the surgery patients receiving prostatectomy, the underlying probability of death in any given month for this cohort of men is 0.28%. That is, of the operative deaths that occur, 57% are expected in the absence of the procedure. When viewed from this context, the observation by Welch and Black (4) that 75% of deaths within 1 month of prostatectomy are not attributed to cancer appears only modestly exaggerated. To be sure, patients who receive surgery are a selected group, because surgeons will generally not operate on patients who appear to be at imminent risk of death or are otherwise seriously medically compromised. Nonetheless, many deaths do occur suddenly and unpredictably. For procedures with much higher operative mortality than prostate cancer— such as pancreatectomy, esophagectomy, or lung resection—we agree that a higher proportion of the operative deaths are likely to be caused by the procedure. However, these are among the sites for which the reclassification proposed by Welch and Black (4) would have the least impact, because relatively few incident cases receive surgery, and the mortality rate of the disease is high relative to the incidence rate. Welch and Black (4) also propose greater efforts to educate individuals who prepare death certificates on basic strategies for ensuring that treatment-related deaths are attributed to cancer. However, this would appear to be a daunting and complex task, with uncertain payoff in improved accuracy, given the vast num-
This paper references
10.1016/0895-4356(94)90089-2
A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer.
Kenneth C. Chu (1994)
10.1093/jnci/94.14.1066
Are deaths within 1 month of cancer-directed surgery attributed to cancer?
H Gilbert Welch (2002)
10.1016/S0895-4356(01)00383-3
Diversity in death certification: a case vignette approach.
Tien Hui Lu (2001)
cate: a comparison
CB Begg (2002)
Apparent changes in cancer
C Percy (1989)
10.1056/NEJM198605083141905
Progress against cancer?
John C. Bailar (1986)
10.7326/0003-4819-129-12-199812150-00005
Accuracy of Death Certificates for Coding Coronary Heart Disease as the Cause of Death
Donald Lloyd‐Jones (1998)
10.1093/jnci/89.1.58
Assessing changes in the impact of cancer on population survival without considering cause of death.
Barry W. Brown (1997)
Apparent changes in cancer mortality, 1968. A study of the effects of the introduction of the Eighth Revision International Classification of Diseases.
Constance Percy (1974)
10.1056/NEJMsa011788
Variations in morbidity after radical prostatectomy.
Colin B. Begg (2002)
10.1002/cncr.10593
Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.
Brenda Kay Edwards (2002)
10.1093/jnci/85.13.1063
Influence of death certificate errors on cancer mortality trends.
David G Hoel (1993)
The relative survival rate: a statistical methodology.
Fred Ederer (1961)
10.1016/S0895-4356(99)00016-5
Colorectal cancer deaths as determined by expert committee and from death certificate: a comparison. The Minnesota Study.
Fred Ederer (1999)
10.1007/978-3-642-83651-0_23
International comparability of coding cancer data: present state and possible improvement by ICD-10.
Constance Percy (1989)
10.1002/1097-0258(20000715)19:13<1729::AID-SIM484>3.0.CO;2-9
Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival.
Kathleen A. Cronin (2000)
Deaths : final data for
DL Hoyert



This paper is referenced by
10.1016/j.scitotenv.2011.03.007
Relative survival after exposure to polychlorinated biphenyls and dioxins: a follow-up of Japanese patients affected in the Yusho incident.
Daisuke Onozuka (2011)
10.1097/COC.0000000000000575
Competing Mortality in Patients With Neuroendocrine Tumors
Soon Khai Low (2019)
10.1177/1536867X0700700304
Modeling of the Cure Fraction in Survival Studies
Paul Lambert (2007)
10.1002/sim.6240
Estimating cancer incidence using a Bayesian back-calculation approach.
Leonardo Carvalho Ventura (2014)
10.1001/archdermatol.2011.264
The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007.
Waqas R. Shaikh (2012)
10.1111/j.1365-2796.2006.01677.x
Interpreting trends in cancer patient survival.
Paul W. Dickman (2006)
10.1002/CNR2.1174
A competing risk analysis of death patterns in male genitourinary cancer
Atanu Bhattacharjee (2019)
10.21037/amj.2017.04.03
Editorial response: “Stereotactic Ablative Radiotherapy vs. Sublobar Resection for Non-Small Cell Lung Cancer: Choosing the Right Patients (an editorial)”
Eric D. Brooks (2017)
10.1245/s10434-013-3173-5
Relative Survival is an Adequate Estimate of Cancer-Specific Survival: Baseline Mortality-Adjusted 10-Year Survival of 771 Rectal Cancer Patients
Ignazio Tarantino (2013)
10.1093/ehjqcco/qcv011
Use of relative survival to evaluate non-ST-elevation myocardial infarction quality of care and clinical outcomes.
Marlous Hall (2015)
10.1200/JCO.2010.33.0472
Causes of death and relative survival of older women after a breast cancer diagnosis.
Mara A. Schonberg (2011)
10.1016/j.envint.2014.07.008
Net survival after exposure to polychlorinated biphenyls and dioxins: the Yusho study.
Daisuke Onozuka (2014)
Patterns and Prediction of Competing Causes of Mortality in Older Adults Diagnosed with Indolent Non-Hodgkin Lymphoma
Laura L Hester (2017)
10.1016/B978-0-12-801565-0.00013-5
Therapies III: Development of Therapies, Costs, and Ethics
Leon P. Bignold (2015)
10.1038/s41598-018-35646-3
Understanding flow dynamics, viability and metastatic potency of cervical cancer (HeLa) cells through constricted microchannel
Binita Nath (2018)
10.1002/bimj.201100069
A minimum version of log-rank test for testing the existence of cancer cure using relative survival data.
Binbing Yu (2012)
10.1002/cncr.27968
Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival.
Chung-Yuan Hu (2013)
Development and application of methodology for the parametric analysis of complex survival and joint longitudinal-survival data in biomedical research
Michael James Crowther MMath (2014)
10.1158/1055-9965.EPI-11-0674
Methods to Assess Adverse Health-Related Outcomes in Cancer Survivors
Kevin Charles Oeffinger (2011)
10.1001/archinte.167.18.1958
Exploring the surgeon volume outcome relationship among women with breast cancer.
Ann Butler Nattinger (2007)
10.2188/jea.JE20150010
Accuracy of Death Certificates and Assessment of Factors for Misclassification of Underlying Cause of Death
Makiko Naka 牧子 Mieno 三重野 (2015)
10.1002/cncr.32136
Cancer-attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014.
Anne-Michelle Noone (2019)
10.1002/ijc.30532
Cure of cancer for seven cancer sites in the Flemish Region
Geert Silversmit (2017)
10.1016/j.canep.2016.12.004
Assessment of lead-time bias in estimates of relative survival for breast cancer.
Therese M-L Andersson (2017)
10.2188/jea.JE20150010
Accuracy of Death Certificates and Assessment of Factors for Misclassification of Underlying Cause of Death.
Makiko Naka Mieno (2016)
10.1016/j.canep.2020.101685
Breast tumor tissue inflammation but not lobular involution is associated with survival among breast cancer patients in the Multiethnic Cohort.
Gertraud Maskarinec (2020)
10.1200/JCO.2011.41.4995
Reply to S.A. Kesikli et al
Peter T. Campbell (2012)
A Prospective Study of the Associations Between Treated DiabetesMellitus and Cancer Outcomes
Hsin-Chieh Yeh (2011)
Quantifying cancer patient survival : extensions and applications of cure models and life expectancy estimation
Therese M.-L. Andersson (2013)
10.1177/1536867X1201200404
Fitting and Modeling Cure in Population-Based Cancer Studies within the Framework of Flexible Parametric Survival Models
Therese M.-L. Andersson (2012)
10.1016/S1470-2045(17)30441-2
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
P D Brown (2017)
Variation in Cancer Outcomes Amongst Children and Young Adults in Yorkshire
M. van Laar (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar